Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|
Free Cash Flow | $33.6M | ($389.9M) | ($436.6M) | ($490.5M) | $1,959.5M | $13.3B | $4,581.0M | ($3,825.0M) |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Moderna, Inc.'s last 12-month Free Cash Flow is ($4,358.0M), based on the financial report for Dec 31, 2024 (Q4 2024).
Over the last year, Moderna, Inc.'s Free Cash Flow growth was 13.9%. The average annual Free Cash Flow growth rates for Moderna, Inc. have been N/A over the past three years, 54.8% over the past five years.
Over the last year, Moderna, Inc.'s Free Cash Flow growth was 13.9%, which is higher than industry growth of (0.1%). It indicates that Moderna, Inc.'s Free Cash Flow growth is Good.